Our results ultimately indicated that a strategy resulting in the destabilization of binding between SPRY4-IT1 and STAU1, using a specific agent such as a small molecule, could be employed to treat tumor patients harboring metastases. This evidence concerns the gene STAU1 and neoplasm.